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Diabetes mellitus type 2 (DM2) affects millions of people worldwide and causes several complications 
for the patient, consuming large sums of financial resources from the health services. This study aims to 
estimate the financial investment of DM2 treatment for glycemic control of the patient, from the point 
of view of the municipal Public Health System (SUS). The Delphi technique was used to validate the 
opinion of a team of judges, specialists in DM2, and health service managers, on the investment necessary 
for glycemic control of patients with DM2 through the application of questionnaires. In order for the 
patient to achieve glycated hemoglobin (A1c) < 7%, an investment of US$ 2,419.06 (value/patient/year) 
is necessary. As the value of A1c increases, investment is reduced. This result reveals the intention to 
allocate resources for the prevention of DM2 and its complications.
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INTRODUCTION
Diabetes mellitus (DM) is a multifactorial metabolic 
disorder (ADA, 2016) that affects about 415 million 
people worldwide (IDF, 2015) and 12 million people in 
Brazil.The diabetes mellitus type 2 (DM2) being the most 
prevalent (90%) (SBD, 2015).
DM causes macro and microvascular complications 
resulting in clinical, financial and social consequences for 
the patient and the health system (Pereira, Nogueira, Silva, 
2015; Silva et al., 2003). Cezaretto et al. (2016) state that 
a multidisciplinary psychoeducational approach is able 
to reduce patients’ cardiometabolic risks, being a viable 
strategy for adopting a healthy lifestyle in the long term 
(Cezaretto et al., 2016).
It should be noted that the direct and indirect 
costs related to DM increase with time (Henriksson, 
Agardh, Berne, 2003). In this way, health services need 
to deal with ever-increasing costs in contrast to scarce 
resources (Guidoni et al., 2009). It is known that the 
onset of complications related to DM increases the cost 
of treatment and it is also known that medication makes 
up 48.2% of the direct costs of DM treatment (Bahia et 
al., 2011). Pharmacoeconomics is a component of the 
economic evaluation of health services that supports 
decision-making and allocation of resources related to 
pharmaceutical services/products (ISPOR, 1986).
In order for management to be able to use the results 
obtained from pharmacoeconomic studies, it is important 
to know the direct, indirect and intangible costs involved in 
the costing system of its activities. In a study conducted by 
Franco et al. (2013), 95.5% of public agents (accountants 
and financial sector employees) interviewed in Paraná 
consider it very important that a cost system be adopted 
in public services, however, 32.8% say they do not know 
the factors that influence the costs of their activities, while 
43.3% consider that cost system information has been 
useful for decision-making by sector managers and leaders 
(Franco et al., 2013).
In Brazil, data regarding the cost of treatment of 
a patient with DM and its complications are still scarce 
(Borges et al., 2011). The absence of this consensus in 
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the literature makes it difficult to analyze costing and 
cost projections in pharmacoeconomic studies. In this 
sense, the present study seeks to estimate the vision of 
public health service managers, and DM specialists, 
regarding financial investment for the treatment of patients 
with DM2, relating these investments to the patient’s 
glycemic control from the point of view of the SUS. In 
this perspective it is important to emphasize that this 
study does not assess the cost of DM treatment, but rather, 
what financial contribution health services management is 
willing to make in order to achieve the patient’s glycemic 
control.
METHOD
This is a methodological study carried out from 
November 2015 to April 2016, in which the Delphi 
Technique (Helmer, Dakley, 1963) was used to estimate 
the financial value that should be invested in the treatment 
of a patient with DM2, according to the values of glycated 
hemoglobin (A1c). The Delphi technique is a methodology 
recommended by the Ministry of Health that takes into 
account the opinion of experts on a certain subject when 
there is no unanimity of opinion due to the lack of scientific 
evidence, or when the information is contradictory (Brasil, 
2013; Revorêdo et al., 2015).
To estimate these data, a questionnaire was 
applied to a team of judges composed of managers of 
the health service of a municipality in the center-west 
of Minas Gerais state (Municipal Secretary, Finance 
Director, Director of Health Care, Pharmaceutical 
Assistance Management, and DM and Systemic Arterial 
Hypertension Management), which deal directly with the 
application of resources and with the implementation 
and evaluation of DM related routines. Specialists 
working with DM patients were also integrated into 
the team of judges. For the selection of specialists, 
the following criteria were considered: specialist with 
an email address available for contact, and belonging 
to the research centers that had a partnership with the 
team of researchers and/or member of the work team of 
the municipality conducting the research. Physicians, 
nurses, nutritionists, physiotherapists, psychologists, 
and pharmacists from the states of Minas Gerais, 
São Paulo, Paraná and Santa Catarina were invited. 
Managers and specialists composed the team of judges 
who were supposed to answer “how much would they 
be willing to invest (value/patient/year) for a patient 
to achieve a range of A1c (< 7%; 7.1 – 8%; 8.1 – 9%; 
9.1 – 10%; 10.1 – 11%; 11.1 – 12%; >12%)”. To support 
this response, were presented data from the literature 
regarding the costs of DM and complications, and data 
of the economy provided by the glycemic control of the 
patient. The questionnaire was previously analyzed by 
five DM specialists for content evaluation.
According to Wright and Giovinazzo (2000) a 50% 
abstention is expected in the first round and 30% in the 
second round of evaluation. Due to the high abstention 
rate, it is recommended that a large number of people be 
invited to participate in the team of judges (Revorêdo et 
al., 2015; Scarparo et al., 2012), therefore, considering 
the research group’s prior experiences, all managers and 
specialists who met the established criteria were invited 
to integrate into the team of judges. The questionnaire was 
sent by email or personally handed to the judges. The team 
of judges assessed whether the questionnaires had been 
answered in the correct way and, in case of inconsistency, 
the judge was notified. If the mistake remained after 
three tries, the questionnaire was excluded. After the first 
round of questions, a compilation containing the average, 
median, minimum, and maximum was resent to each 
judge that could assess whether their previous answer 
would be modified or maintained according to the panel 
of specialists. The answers were considered valid when a 
concordance of 80% was obtained considering the answers 
of all the judges. The concordance was calculated by 
means of the total answers of all the researchers and the 
total of modified answers after each round (Figure 1). The 
normality of the data was evaluated using the Kolmogorov 
Smirnov test.
The monetary amounts presented in the results 
expressed in dollars were converted using the quotation 
on April 30, 2016 (R$ 3.451). 
RESULTS AND DISCUSSION
The invitation to respond to the questionnaire was 
sent to six managers and 64 specialists via e-mail. Five 
managers and 20 specialists responded (64% abstention). 
The questionnaires were delivered personally to judges 
from the state of Minas Gerais and the city of Ribeirão 
Preto (SP) and sent via e-mail to judges from the other 
states (São Paulo, Santa Catarina and Paraná). Four 
managers and 17 specialists returned the completed 
questionnaire (16% abstention). A questionnaire was 
excluded for noncompliance with the response guidelines. 
It is observed that the abstention rate was higher than 
expected in the first round of questions, however, in the 
second round this index is lower (Wright, Giovinazzo, 
2000). It is expected that the high abstention of the first 
round will not impact the results. In the second round, two 
managers and a specialist made changes to the answers. 
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The agreement was 83.3% and the answers were validated 
by the Delphi technique. The medians of the answers make 
up the final result presented below.
According to the consensus of experts, US$ 2,419.06 
should be invested annually (value/patient/year) so that the 
patient achieves A1c < 7%. The value of the investment 
decreases as the value of A1c increases, as can be seen in 
Table I.
In a survey conducted by Bahia et al. (2011) in eight 
Brazilian cities, considering different levels of complexity, 
the annual cost of a patient with DM for the health service 
is US$ 2,108.00. Henriksson, Agardh and Berne (2000) 
concluded that patients with associated microvascular 
and macrovascular complications may have treatment 
costs tripled when compared to patients without these 
complications. Compared with the present study, it is 
presumed that the prevention of complications is the main 
objective of the managers, since there is an intention to 
place the largest volume of financial resources for the 
patient to achieve glycemic control (A1c <7%).
In a Brazilian study by Obreli-Neto et al. (2015), it 
was verified that the reduction of 0.7% in A1c provides a 
saving of US$ 660.00 per patient per year. 
A study by Arredondo and Icaza (2011) in Mexico 
predicted a 33% increase over three years in direct and 
indirect costs related to DM, and the modification of risk 
factors and care models for DM treatment is the only 
alternative for these costs not to become unsustainable for 
health services (Arredondo, Icaza, 2011).
Another recent study that assessed the DM cost for 
2015 in Latin America and the Caribbean found a value 
of 123 billion dollars/year, with resources mostly destined 
to the treatment of complications and with an estimated 
TABLE I - Annual investment of the health service management 
according to glycemic control of the patient with diabetes 
mellitus type 2 (DM2), after consensus of specialists. Source: 
Prepared by the author. N = 21, 2015-2016
A1c (%) Median (min. – max.) (U$)
< 7 2,419.06 (1,159.15 – 3,767.24)
7.1 - 8 2,236.73 (1,014.26 – 3,152.89)
8.1 – 9 1,683.67 (869.36 – 2,680.54)
9.1 – 10 1,263.48 (145.71 – 2,405.24)
10.1 – 11 744.75 (145.71 – 2,086.47)
11.1 – 12 667.67 (145.71 – 3,152.89)
> 12 595.22 (145.71 – 3,783.47)
Legend: A1c - glycated hemoglobin. Min. - minimum. 
Max. - maximum
FIGURE 1 - Description of the evaluation stages of the judges in the Delphi technique. Source: Prepared by the author. Adapted 
from Sousa and Turrini, 2012 (16). Legend: DM2 - Diabetes Mellitus Type 2.
A. C. O. Gonçalves, M. S. Cazarim, C. Sanches, L. R. L. Pereira, A. O. Baldoni
Braz. J. Pharm. Sci. 2019;55:e17197Page 4 / 6
per capita cost between US$ 1,088.00 and US$ 1,818.00 
(Barcelo et al., 2015).
The American Diabetes Association survey 
estimated a 245 million/year cost, with a US$ 7,900.00 
per capita cost, and with 61% of the resources being 
destined to the payment of hospitalizations and of drugs 
related to DM complications (ADA, 2013). A systematic 
review carried out in the Netherlands estimated that the 
direct and indirect costs of DM treatment in 2016 was 
6.8 billion euros, and that about 4 billion of that amount 
was destined to the treatment and loss of productivity 
related to DM complications (Peters et al., 2017). A 
recently performed systematic review which considered 
the costs involved in DM treatment concluded that 
prevention, early DM detection and good quality of 
the services provided to the patient are essential for the 
reduction in the occurrence of complications (Mustapha 
et al., 2017). Considering the afore-mentioned, and the 
findings of this study, it is important to highlight that 
the greater the number of complications, the higher the 
cost of treatment and the less managers will be willing 
to invest. This stresses the need for DM-complication 
prevention strategies.
Observing the results of the present study, it is 
noted that the values suggested by the team of judges are 
in accordance with the per capita cost values practiced in 
Brazil. However, they are higher than the Latin American 
and Caribbean values and lower than the USA values. 
It is also noted that, when the possibility of investing 
is stratified according to the A1c values, prevention 
of complications is the main goal of the judges, as the 
intention is to allot more resources so that patients 
can achieve glycemic control (A1c≤ 7%). This fact 
corroborates the literature, since complications related 
to DM consume a considerable amount of financial 
resources. Thus, preventing complications from arising is 
consequently the rational way to apply and optimize the 
resources available.
This scenario highlights a paradox for the healthcare 
system, as the need for resource allotment for DM 
prevention is understood. However, it is necessary to deal 
with a reality in which patients struck by the disease show 
complications and require large sums of money for their 
treatment. From the point of view of equity, resources are 
allotted in order best to serve those who are most in need; 
nevertheless, from the point of view of integrality, it is 
necessary to implement health promotion and worsening 
prevention actions so that all healthcare needs can be met 
(Brasil, 1990).
This is why it is necessary for healthcare services 
to constantly seek more efficient alternatives for glycemic 
control of DM patients, since preventing complications 
provides the patient with better quality of life.
The use of quality databases and information in the 
management of health services is a necessity reinforced by 
several authors (Drachler et al., 2003; Bittar et al., 2009; 
Lima et al., 2009). Guidoni and collaborators (2012) used 
database searches to trace the pharmacological profile 
of patients with DM in Ribeirão Preto (SP, Brazil). Data 
and information analyzes were used in the creation of 
an epidemiological and economic profile for patients 
in renal replacement therapy (Szuster et al., 2009). 
Berretta, Lacerda, Calvo (2011) proposes an evaluation 
model of municipal management for health planning 
and puts information management as one of the main 
axes in assessing the quality of management. during 
the development of this model, among the participating 
municipalities, the satisfaction with updating the databases 
was higher than 70%, however, in the final result of the 
evaluation, only 23.6%. The management for health 
planning was considered effective in 23.6%.
In this sense the result of this study becomes 
innovative, as it correlates willingness to invest financially, 
and glycemic control capability. This provides reflection 
about the implementation of new health technologies, thus 
highlighting the need to assess the costs and benefits of 
adopting a healthcare technology or process to be offered 
at a healthcare unit, something that rarely happens in the 
Brazilian healthcare system.
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